ZURICH/BERLIN, Dec 4 (Reuters) - The Swiss blue-chip SMI was seen opening 0.3 percent lower at 9,080 points on Tuesday, according to premarket indications by bank Julius Baer . Here are some of the main factors that may affect Swiss stocks:
Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with a form of haemophilia, the drugmaker said.
Roche also said that a study showed its drug Venclexta, being developed with rival AbbVie, produced deep responses in two common types of leukaemia.
* Zur Rose Group said 10.4 percent shareholder KWE Beteiligung had reached a settlement with its house bank after the bank failed to execute an order to participate in the recent rights issue. However, the deal does not include delivery of shares or purchases on market to boost its shareholder back to pre-rights issue levels.
* Orell Fuessli Holding said its Chief Executive Martin Buyle will leave the printing and retail group at the end of 2019. The company said it expects an operating profit, before special effects, in 2018 at a similar level to the previous year.
* Cicor Technologies said it had won a contract worth more than 20 million francs to supply thin film substrates to a European aerospace company.
Inflation data for November due at 0815 GMT. Consumer prices seen falling 0.1 percent m/m and rising 1.0 percent y/y.
Reporting by Zurich Newsroom and Berlin Speed Desk